Photo of Scott A. McMurry

Scott McMurry, PhD, is an associate in Mayer Brown's New York office and a member of the Intellectual Property practice. He focuses his practice on pharmaceutical patent litigation, particularly Hatch-Waxman litigation and related inter partes reviews, and on patent counseling, including global patent portfolio management and due diligence.

Scott regularly assists in a wide range of life science patent matters. He has worked on all phases of bet-the-company litigations up to trial, helping to protect flagship, multi-billion dollar drug products. Scott has experience preparing witnesses for testimony, including experts, inventors and company representatives. He regularly reviews intellectual property for licensing, merger and acquisition matters, and prepares freedom to operate and patentability opinions.

Continue Reading

Antibody-based serology tests and PCR tests for coronavirus are being approved at a breakneck pace by the U.S. Food and Drug Administration under newly relaxed guidelines. As recently as May 8th, the FDA issued an emergency approval for another serology test for coronavirus antibodies, an immunofluorescent sandwich assay necessarily developed in under six months. https://www.fda.gov/media/137886/download. Scientists also just reported the identification of neutralizing antibodies that are unique to SARS-CoV-2, which may trigger a flood of new diagnostic tests. https://www.nature.com/articles/s41586-020-2380-z. Diagnostic tests have proven difficult to patent under
Continue Reading A Glimmer of Light for Immunotherapy Diagnostic Method Patents